Tiziana Life Sciences PLC Tiziana to Present at Biotech Showcase Digital
January 11 2021 - 8:48AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
11 January 2021
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Life Sciences to Present at Biotech Showcase Digital
2021
NEW YORK and LONDON - 11 January 2021 (GLOBE NEWSWIRE) - Tiziana
Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the
"Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious diseases,
today announced that it is participating in Biotech Showcase(TM)
2021 and providing an on-demand company presentation. Registered
attendees to Biotech Showcase can now access recorded company
presentations prior to the actual event. 24x7 on-demand access
allows attendees to view presentations at their convenience,
avoiding conflicts with busy meeting schedules during the main
event week.
Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences,
commented, "I look forward to sharing our exciting story with
conference attendees. With topline data from our COVID-19 trial
expected this month, multiple Phase 2 trial launches expected in
2021, and the potential application of Foralumab in a wide range of
autoimmune and inflammatory diseases longer-term, we are well
positioned to achieve a series of important milestones that can
provide a positive and lasting impact on our valuation in the
months and quarters ahead."
Biotech Showcase, produced by Demy-Colton and EBD Group, is an
investor conference focused on driving advances in therapeutic
development by providing a sophisticated networking platform for
executives and investors that fosters investment and partnership
opportunities. The conference takes place each year during the
course of one of the industry's largest gatherings and busiest
weeks.
"We are delighted that Tiziana Life Sciences will be presenting
at Biotech Showcase this year," said Sara Demy, CEO of Demy-Colton.
"Biotech Showcase is a prime occasion for life science
entrepreneurs and investors to come together to discover the
potential of innovative technologies that will drive the future of
drug discovery."
To learn more about registration options for Biotech Showcase,
click here .
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
Milciclib, the Company is also developing Foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis
(NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
U.S. Investor Contact:
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABSGDBSSBDGBB
(END) Dow Jones Newswires
January 11, 2021 09:48 ET (14:48 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024